No Data
Ainos Receives Institutional Review Board Approval From Shuang Ho Hospital For Its Trial Of VELDONA In Sjögren's Syndrome
Ainos Third Quarter 2024 Earnings: US$0.33 Loss per Share (Vs US$0.73 Loss in 3Q 2023)
Express News | Ainos Inc - Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities
Ainos Files Complaints With Nasdaq MarketWatch And The SEC Of Concerns Over Large-Volume Sell Orders, Says It 'Suspects That These Trading Activities May Involve Regulatory Violations'
Ainos Q3 Net Loss $3,699,317
10-Q: Q3 2024 Earnings Report
No Data
No Data